CCCC c4therapeutics.com: Enterprise Value to EBITDA Ratio

The market valuation dynamics help analyze the value of C4 Therapeutics, Inc. (CCCC), which utilizes TORPEDO technology for the complete degradation of harmful proteins via oral administration. The current metric stands at 0.00. The business relies on external investment due to a lack of profitability during the drug development stage. C4 Therapeutics, Inc. (CCCC) is currently scaling its portfolio of innovative drugs targeting hard-to-reach molecules to modernize cancer treatment methods.

CCCC (C4 Therapeutics Inc) Enterprise Value to Operating Income Before Depreciation Ratio history from 11/23/2025 to 11/13/2026

Comprehensive metric breakdowns and analytics for c4therapeutics.com (CCCC)

- stock price and consensus target price:

Stock Quotes C4 Tx|CCCC - Average Forecast Price

- company stock capitalization data:

Market Valuation C4 Therapeutics Corp|CCCC - Value Adjusted for Debt and Cash

- business book valuation details:

Accounting Value per Share C4 Therapeutics|CCCC - Total Net Assets|Market Capitalization to Book Value Ratio c4therapeutics.com|CCCC - Company Total Assets

- debt and solvency information:

- net income and valuation multiples indicators:

CCCC - Company Net Income|Projected Future Earnings C4 Therapeutics, Inc.|CCCC - Price to Earnings Multiple|Projected Price to Earnings C4 Therapeutics, Inc.|CCCC - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio C4 Therapeutics Corp|CCCC - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) C4 Therapeutics|CCCC - Earnings per share for the trailing year|Quarterly EPS earnings growth c4therapeutics.com|CCCC - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year C4 Therapeutics, Inc.

Basic company analysis:C4 Tx CCCC

The EV/EBITDA multiple compares the total enterprise value, including debt, with operating profit before depreciation and amortization. This metric provides a real-time assessment of cash flow changes in quarterly reports by excluding the impact of the tax regime. Analyzing the EV/EBITDA valuation level allows for the determination of the fair value of assets. For C4 Therapeutics, Inc. (CCCC), this is critical when evaluating the effectiveness of strategic alliances in oncology drug development without resorting to capital-intensive mergers.

Competitor analysis

Genmab US - Enterprise Value to EBITDA Ratio|Exelixis Inc. (EXEL) - Company Value to EBITDA|NUVL: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation KYMR (kymeratx.com)|IDYA (IDEAYA Biosciences, Inc.) - Enterprise Value to EBITDA Ratio|ELVN: Enterprise Value to Operating Income Before Depreciation Ratio|ORIC (ORIC Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple Relay Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nurix Therapeutics (NRIX)|TYRA (tyra.bio) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple VSTM (Verastem)|Enterprise Value to EBITDA Multiple Monte Rosa Therapeutics Inc|Cullinan Therapeutics Inc - EV/EBITDA Multiple|Company Value to EBITDA Immuneering Corp.|BDTX (Black Diamond) - Enterprise Value to EBITDA Ratio|RPTX: Enterprise Value to Operating Income Before Depreciation Ratio|PMVP (PMV Pharmaceuticals, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Karyopharm KPTI|EV/EBITDA Multiple PPCB|Cyclacel - Enterprise Value to Operating Income Before Depreciation|Aadi Bioscience, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ALRN|BPMC: Enterprise Value to EBITDA Ratio|GlycoMimetics, Inc. - Enterprise Value to Operating Income Before Depreciation Ratio|SWTX: EV/EBITDA Multiple